About DILIsym
DILIsym is a company based in Durham (United States) founded in 2014 was acquired by Simulations Plus in May 2017. DILIsym operates in a competitive market with competitors including Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others.
- Headquarter Durham, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Latest Funding Round
$1.5 M (USD), Grant
Jan 17, 2019
-
Investors
Simulations Plus
& 1 more
-
Employee Count
Not available
-
Acquired by
Simulations Plus
(May 01, 2017)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Funding Insights of DILIsym
Investors in DILIsym
DILIsym has secured backing from 2 investors, including institutional investors. Prominent investors backing the company include Simulations Plus and National Institute of Diabetes and Digestive and Kidney Diseases.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Research and health information on diabetes and kidney diseases are provided by NIDDK.
|
Locked | Locked | Locked | |
|
Simulation software is developed for chemoinformatics and drug discovery.
|
Locked | Locked | Locked |
Investor details for DILIsym
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by DILIsym
Investment portfolio details for DILIsym
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - DILIsym
Detailed financials for DILIsym
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Dilisym Comparisons
Peer comparison for DILIsym
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of DILIsym
DILIsym operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Insitro, HotSpot Therapeutics, TOLREMO therapeutics, Certara and Inpharmatica, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
An AI-enabled platform is developed for infectious disease treatment.
|
|
| Locked | Locked | Locked |
Developer of a platform for protein function analysis
|
|
| Locked | Locked | Locked |
Anti-cancer small molecules are developed to target drug resistance pathways.
|
|
| Locked | Locked | Locked |
Provider of a platform for in silico drug discovery and consulting services
|
|
| Locked | Locked | Locked |
Developer of predictive informatics based platform for drug discovery
|
|
| Locked | Locked | Locked |
Immune system-based drugs are discovered via biological data analytics.
|
Detailed competitors of DILIsym
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Dilisym
Complete news archive for DILIsym
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about DILIsym
DILIsym was founded in 2014 and raised its 1st funding round 5 years after it was founded.
DILIsym is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Brett Howell is the current CEO of DILIsym.
Founded in 2014 and based in Durham, United States, DILIsym operates in the pharmaceutical software sector. Quantitative toxicology tools are offered to model drug-induced liver injuries and predict patient-specific toxicities. Hazards from individual drug molecules are analyzed through an in silico graphical interface, supporting investigations into compounds, doses, and durations. Integration with the companys SimPops platform enables simulation of inter-individual variability in drug responses across virtual patient populations.
DILIsym's top competitors include Insitro, HotSpot Therapeutics and Certara.
DILIsym has 2 investors. Key investors include Simulations Plus, and National Institute of Diabetes and Digestive and Kidney Diseases.